RxDoctor Payments Data

Walter Porter

Family · Chattanooga, TNNPI 1083191191

Payments from drug & device makers

$3,457in general payments, 2019–2025

Across 186 payments — averaging $18.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$553
  • Novo Nordisk$422
  • Pfizer$241
  • Incyte Corporation$219
  • Lilly USA, LLC$203
  • Biohaven Pharmaceutical Holding Company Ltd.$169
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$3,23794%
  • Education$2206%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,457 in reported general payments places this provider in the 85th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib13$182,281
EliquisApixaban13$12,115
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$8,028
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen34$857
Atorvastatin Calcium41$714
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen38$518
Gabapentin26$394
Rosuvastatin Calcium27$350
Letrozole14$315
Famotidine12$310
Levothyroxine Sodium36$255
Losartan Potassium15$245
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst13$232
Tamsulosin Hcl17$227
Ondansetron OdtOndansetron11$219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$241$194,39626 claims
GSKTrelegy Ellipta$20$8,02811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,706 family providers in Tennessee.

Other family in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →